TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
CRDF

Cardiff Oncology Inc

Healthcare · Biotechnology

1.30$ -2.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CRDF
Line item 2004 2005 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– – 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
– – 85.5% 55.6% 81.0% 92.8% 96.0% 94.5% 95.7% 88.6% 77.1% 90.1% 86.8% 99.0% 97.7% 95.8% 94.8% 97.8% 97.2%
– – 72.4% 11.5% 67.4% 92.8% 95.1% 94.5% 94.5% 86.2% 67.0% 80.8% 77.9% 97.2% 8.0% 14.1% 26.5% 53.0% 28.2%
– – 72.4% 11.5% 67.4% 92.8% 95.1% 94.5% 94.5% 86.2% 67.0% 80.8% 77.9% 97.2% 94.2% 90.6% 91.7% 94.4% 94.2%
– – 3.9% 14.6% 9.5% 1.4% 0.3% 0.2% 0.1% 0.2% 0.6% 1.2% 1.6% 0.2% 0.4% 0.7% 0.4% 0.8% 0.3%
– – – – – -2.0% – -1.5% 0.0% – 0.0% – 0.0% – – – – – –
– – – – – – 2.8% 2.9% 3.8% 8.7% 19.8% 9.2% 6.7% 0.5% 0.3% 1.1% – – –
– – 598.7% 1,075.2% 507.1% 81.4% 24.9% 71.1% 31.8% 55.0% 47.0% 28.8% 44.1% 4.9% 6.1% 8.5% 14.6% 14.7% 26.7%
– – 422.4% 668.0% 137.6% 6.3% 7.4% 15.5% 11.5% 17.7% 32.1% 20.9% 36.5% 4.5% 4.4% 6.7% 12.8% 13.8% 26.5%
– – 277.6% 455.9% – – 0.7% 6.6% 7.3% 5.4% 10.8% – 6.6% 0.6% 0.4% 0.6% 0.8% 0.7% 1.2%
– – 108.7% 124.5% 89.3% 1.5% 1.1% 9.0% 1.5% 2.6% 6.7% 4.7% 5.0% 1.0% 1.0% 1.7% 2.4% 5.0% 13.1%
– – – – – – – – 15.7% 32.3% – – – – – – – – –
– – -498.7% -975.2% -407.1% 18.6% 75.1% 28.9% 68.2% 45.0% 53.0% 71.2% 55.9% 95.1% 93.9% 91.5% 85.4% 85.3% 73.3%
– – -4,714.5% -8,067.0% -4,195.2% -473.2% -246.9% -281.7% -152.4% -337.0% -1,408.6% -1,356.1% -1,596.3% -171.8% -173.7% -256.6% -415.9% -395.3% -694.9%
– – 9.2% 19.4% 13.0% 1.6% 0.9% 0.9% 0.5% 1.0% 3.9% 16.4% 45.6% 15.5% 26.1% 37.5% 54.7% 49.0% 108.0%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?